Sepsis, a manifestation of the body's inflammatory response to injury and infection, has a mortality rate of between 28%-50% and affects approximately 1 million patients annually in the United States. Currently, there are no therapies targeting the cellular/molecular processes driving sepsis that have demonstrated the ability to control this disease process in the clinical setting. We propose that this is in great part due to the considerable heterogeneity of the clinical trajectories that constitute clinical "sepsis," and that determining how this system can be controlled back into a state of health requires the application of concepts drawn from the field of dynamical systems. In this work, we consider the human immune system to be a random dynamical system, and investigate its potential controllability using an agent-based model of the innate immune response (the Innate Immune Response ABM or IIRABM) as a surrogate, proxy system. Simulation experiments with the IIRABM provide an explanation as to why single/limited cytokine perturbations at a single, or small number of, time points is unlikely to significantly improve the mortality rate of sepsis. We then use genetic algorithms (GA) to explore and characterize multi-targeted control strategies for the random dynamical immune system that guide it from a persistent, non-recovering inflammatory state (functionally equivalent to the clinical states of systemic inflammatory response syndrome (SIRS) or sepsis) to a state of health. We train the GA on a single parameter set with multiple stochastic replicates, and show that while the calculated results show good generalizability, more advanced strategies are needed to achieve the goal of adaptive personalized medicine. This work evaluating the extent of interventions needed to control a simplified surrogate model of sepsis provides insight into the scope of the clinical challenge, and can serve as a guide on the path towards true "precision control" of sepsis.
Approximately 1 million people will be diagnosed with sepsis, a condition with a mortality rate ranging from agent-based model (ABM) of systemic inflammation, the Innate Immune Response agent-based model (IIRABM). 28 We propose to use the existing IIRABM as a surrogate proxy system [11] for the investigation of potential control 29 strategies for sepsis. We note that while the model does not contain a comprehensive list of all signaling 30 mediators present in the human body, all relevant cellular behaviors are represented. The named cytokines in 31 this model are those that are most often associated with the available behavior rules in the current literature [12] . 32 The IIRABM is a two-dimensional abstract representation of the human endothelial-blood interface. This 33 abstraction is designed to model the endothelial-blood interface for a traumatic (in the medical sense) injury, and 34 does so by representing this interface as the unwrapped internal vascular surface of an azimuthally averaged 2D 35 projection of the terminus for a branch of the arterial vascular network. This abstraction serves two primary 36 purposes: to allow circumferential access to the traumatic injury by the innate immune system, and to 37 incorporate multiple levels if interaction between leukocytes and tissue. The IIRABM utilizes this abstraction to 38 simulate the human inflammatory signaling network response to injury; the model has been calibrated such that 39 it reproduces the general clinical trajectories of sepsis (see supplemental material for details). The IIRABM 40 operates by simulating multiple cell types and their interactions, including endothelial cells, macrophages, 41 neutrophils, TH0, TH1, and TH2 cells as well as their associated precursor cells. The simulated system dies when 42 total damage (defined as aggregate endothelial cell damage) exceeds 80%; this threshold represents the ability of 43 current medical technologies to keep patients alive (i.e., through organ support machines) in conditions that 44 previously would have been lethal. The IIRABM is initiated using 5 external variables -initial injury size, 45 microbial invasiveness, microbial toxigenesis, environmental toxicity, and host resilience. In previous work [13] , 46 we have performed a parameter sweep over these variables to determine the plausible boundaries for conditions 47 that could be considered clinically relevant. These are parameter sets that can lead to multiple outcomes -48 complete healing, death by infection, or death from immune dysregulation/sepsis. 49 Additionally, the IIRABM has been used to perform in silico clinical trials of mediator-directed therapies via 50 the inhibition or augmentation of single and specific cytokine synthesis pathways [12] . Those studies accurately 51 reproduced unsuccessful clinical trials, as well as the non-efficacy of hypothetical interventions; however to date 52 no effective putative interventions have been discovered.
53
The human innate immune response, and specifically in terms of sepsis, can be characterized through 54 measurement of various biomarkers, including the pro-inflammatory and anti-inflammatory cytokines included in 55 the IIRABM [14] . This implies that the system can be characterized by its state at some specific time, and 56 therefore we apply that same perspective to our investigations with the IIRABM. At each time step, the IIRABM 57 measures the total amount of cytokine present for all mediators in the model across the entire simulation. The 58 ordered set of these cytokine measurement creates a high-dimensional trajectory through cytokine space that 59 lasts throughout the duration of the simulation (until the in silico patient heals completely or dies). Prior 60 analysis of these trajectories has shown that the aggregate output of the IIRABM behaves as a Random
61
Dynamical System (RDS) with chaotic features [13] (in the sense that future simulation state can be sensitive to 62 initial conditions). A Random Dynamical System [15] can be described by the triplet (S, Γ, Q) where S is the 63 state space, Γ is a family of maps which maps S back onto itself (often referred to as the "equations of motion"), 64 and Q is some probability distribution on Γ. Simply put, an RDS is a system in which the equations of motion 65 (in this case, the equations which give the aggregate cytokine value for the system at a specific instance in time) 66 contain elements of randomness. A detailed discussion of this, and more formal definition, can be found in [16] . 67 System state in the IIRABM can be defined by a vector of cytokines, C(t), in which each element of 68 C(t), C i (t), is the total amount of an individual cytokine present in the simulation at that instance in time. The 69 cytokines which comprise this vector are: Platelet-activating factor (PAF), Tumor necrosis factor alpha (TNFα), 70 Soluble tumor necrosis factor receptors (sTNFr), Interleukin-1 (IL1), soluble interleukin-1 receptors (sIL1r),
71
Interleukin-1 receptor antagonist (IL1ra), Interferon-gamma IFNγ, Interleukin-4 (IL4), Interleukin-8 (IL8),
72
Interleukin-10 (IL10), Interleukin-12 (IL12), and Granulocyte colony-stimulating factor (GCSF). At each time 73 step, C(t) is given by:
where c i,n (t) is the individual cytokine concentration seen by the endothelial cell at a specific grid point and N is 75 the total number of endothelial cells which make up the endothelial surface. The random element comes from the 76 calculation:
This equation contains four primary terms: f i,n,EC ( c(t)) is the amount of cytokine i produced by endothelial cell 78 n in response to current cytokine concentrations; n,A p n,A f n,i,A ( c(t)) is the sum of the responses of all other 79 cell types, indexed with A, at the location of endothelial cell n, where p n,A is the population of a specific cell 80 type at that location; n D i c i,n (t) represents the amount of cytokine i which diffuses into location n (according 81 to the associated diffusion constant, D i ) from the neighboring cell locations, denoted by n ; and λ i c i,n (t) is the 82 amount of cytokine at cell location n that degrades at each time step according to degradation constant λ i . The 83 randomness in this model comes from the term p n,A . This population is stochastically random in two ways: 1) in 84 the absence of cytokine markers, inflammatory cell movement follows a random walk, and 2) cellular 85 differentiation of inflammatory cells proceeds according to a probability distribution parameterized by current 86 cytokine concentrations. We note that this explicit randomness does not comprise the entire uncertainty present 87 in the model. The aggregation of individual cytokine concentrations into a single measure conceals any spatial 88 information present in the simulation. Due to this, future behaviors can appear to be random when, in reality, an 89 epistemic uncertainty (as opposed to intrinsic or "real" stochasticity randomness) prevents an accurate prognosis. 90 A high-level overview of this system and visual depiction of the functional rules governing cytokine production 91 can be seen in Fig. 1 .
92
Discovery of an effective or optimal intervention can then be viewed as a nonlinear optimization of a control 93 problem [17] [18] [19] . Genetic Algorithms (GA) [20] and Evolutionary Computing have been used to optimize a wide 94 variety [21] of nonlinear systems. Medical applications of GA include vaccine dosing strategies and protein 95 binding site prediction [22, 23] . Given a sufficiently validated model, and interpretation of the development of an 96 intervention/control strategy to be a nonlinear optimization problem, GA's can also be utilized to develop 97 complex treatment and control strategies. The parameter set (invasiveness=2, toxigenesis=5, host resilience=0.1, environmental toxicity=2) upon which the 100 GA was trained generated a set of simulations that led to a final outcome of death by sepsis with a probability of 101 82%, therefore representing a challenging case to digitally "cure." Table 1 displays results from a variety of 102 interventions that minimized their associated fitness function functions. The first column displays the number of sequential interventions (spaced 12 hours apart); the second column 104 displays the length of the intervention in simulation time steps; the third column displays the general probability 105 of death for this specific condition (parameter set) after intervention; the fourth column displays the probability 106 of death for the specific in silico patient upon which the GA was trained. The general probability of death was 107 calculated by starting the simulation with 100 distinct RNG seeds, applying the selected intervention, and 108 running the simulation to completion. The probability of death for the specific patient was calculated by starting 109 the simulation with a specific RNG seed, reseeding the RNG 100 times at the start of the intervention sequence, 110 applying the intervention, and running the simulation to completion (either complete healing or death). We have 111 previously characterized the stochastic properties of the trajectory space of the IIRABM in [13] , and note the 112 existence 3 distinct regions of state space: 1) the region of space under the influence of the Life Attractor -113 trajectories in this region will always lead to a state of complete healing; 2) the region of space under the 114 influence of the Death attractor -trajectories in this region will always lead to complete system failure and 115 death; and 3) the "stochastic zone" -trajectories in this region are influenced more strongly by random effects 116 (stochastic randomness and epistemic uncertainty) than by the effects of either of the aforementioned attractors. 117 At the time point when the intervention is started, the system is still in the "stochastic zone," and thus a 118 given intervention will not have a guaranteed effect; rather, it changes the probabilistic future outcome 119 distribution to favor a state corresponding to greater health. Thus, a subtle effect sustained over time causes a 120 significant improvement in mortality rates. Throughout the course of this work, we initiate our interventions 12 121 hours post-simulated injury. The GA has found an effective intervention which begins at this point, however, if 122 stochasticity leads an in silico patient to a sufficiently different location in cytokine state-space, the stochastic 123 failure of the first stage of the intervention will lead to further failure at subsequent stages. The nature of these 124 dynamics explains the phenomenon of "non-responders" to the putative interventions as defined at various time 125 points during an individual trajectory; ultimately "non-responders" represent trajectories that are either not 126 driven out of the stochastic zone by our proscribed duration of therapy or those whose stochastic response lead 127 them to a region of parameter space in which the intervention no longer alters the future outcome probability 128 distribution to favor a state of increased health.
129
The best solution (that which minimized the probability of death for both the specific patient case and the 130 general case) was found by using 8 sequential interventions. For the specific patient upon which the GA was 131 trained, the probability of death was reduced from 68% to 12% through application in the intervention shown in 132 Fig 2; for the general case, the probability of death with this intervention was reduced from 82% to 16%. This intervention is represented as a three-dimensional bar graph in Fig 2. The height of the bars along the z-axis 134 represents the log2 of the intervention multiplier; the x-axis enumerates the interventions; the y-axis shows which 135 cytokine has its protein synthesis augmented or inhibited according to its associated bar. In order to explore the 137 generalizability of this intervention, 138 we tested it against all parameter 139 sets that generated a mortality 140 rate between 1 and 99% -this 141 is the population of parameter sets 142 that have been defined as "clinically 143 relevant" [13] . The results of this 144 test are shown in Fig. 3 of parameter sets. Fig. 3 , Panels 162 C-F show the shifts in mortality rate 163 distribution for more narrow ranges of mortality. We note that Fig. 3 , panels E and F appear to have a bimodal 164 distribution (also hinted at in Panel D); this bimodal distribution occurs because as the severity of the simulated 165 condition increases, the likelihood of a given stochastic replicate being a "non-responder" to a standardized 166 treatment also increases.
167
The phenomenon of "non-responders" provides an excellent argument for adaptive personalized medicine, that 168 is, the need to adapt a therapeutic strategy based on an individual's response to therapy ("in silico clinical trials 169 of 1"), with the goal of returning a system to a state of health. To further explore this, we investigated the cases 170 that were unable to be cured using the derived intervention. Fig. 4A shows the total oxygen deficit trajectories 171 for the average of all the simulations that healed when using the optimal intervention and for a single instance of 172 the simulation that does not heal; Fig 4B shows the neutrophil population and Fig 4C shows the total systemic 173 GCSF. After three sequential interventions, it is apparent that this patient has a stronger response to GCSF 174 stimulation, and thus a higher neutrophil population. As this difference continues to compound over time, 175 interventions later in the sequence lose their efficacy (as they are optimized for a system in a different state).
176
After the application of three sequential interventions, it is apparent that this particular in silico patient is not 177 responding desirable to the therapy. We pause the simulation at this point and use the GA to find a sequence of 178 5 more interventions that could heal the system. The newly derived final 5 interventions are compared with the 179 old intervention in Fig. 5 . This shifted the probability of death for that patient (at the time in which the 180 intervention is changed) from 75% to 8%. This success suggests that an algorithm that adapts interventions 181 based on system response could be more successful than a GA. Fig 4. Panel A displays the oxygen deficit (an inverse measure of the system's health) for an intervention non-responder (red) compared to the average oxygen deficit for intervention responders (blue) over time. Panel B displays the total GCSF for the non-responder and the responder average; panel C displays the total neutrophil population for an individual non-responder and the responder average. In this case, the non-responder does not end up healing due to a hyper-productive response to GCSF pathway stimulation, which leads to a surplus neutrophil population; this patient ultimately dies due to inflammation, which is exacerbated by the applied intervention. Fig 5. The bar graph on the left shows the final 5 interventions in a sequence of 8 which showed the greatest success in healing the most in silico patients. Note that the first three intervention steps are identical to those shown in Fig. 2 . The bar graph on the right shows an alternate intervention sequence that was generated by training the genetic algorithm on a patient who was non-responsive to the original intervention. The in silico patients received identical interventions for the first three time points. At time point3, a significant deviation from expected behavior is noted in the non-responder. At this time point, the simulation is halted and used to populate the sample set for a new run of the genetic algorithm. When given the original intervention, this patient has a 75% chance of death at 60 hrs post-injury; the alternate intervention lowers this chance to 8%.
Discussion

183
The human inflammatory signaling network as represented by the IIRABM is nonlinear, stochastic, and chaotic 184 system that lacks a unique set of analytical equations that can adequately describe it. Designing an effective 185 strategy to control such a system requires the exploration of an astronomically large search space -in the case of 186 8 sequential interventions with 9 defined augmentation/inhibition strengths, there are approximately 1091 187 combinations that can be applied to the system. Given the size of this space, we make no claim that we have 188 found the globally optimal intervention for our model, given a fixed set of parameters; rather, we have shown 189 that GA can be used to find a "good-enough" solution that shows success (though not perfection) at treating a 190 range conditions leading to death by sepsis.
191
Longer duration therapies were more successful than shorter therapies due to the stochastic nature of the 192 IIRABM and its response to perturbations (see supplemental material). All interventions are performed on in 193 silico patients whose system state is either in the stochastic zone or under the influence of the death attractor (in 194 which case their trajectories would have to pass through the stochastic zone on the way to health). When the 195 system state is in the stochastic zone, the effects of randomness can be stronger than the effects of either of the 196 attractors which influence the system; subsequent states will fall within some probability distribution (which is 197 discoverable via pausing the simulation and reseeding the random number generator several times) based on the 198 current state. In that sense, we could also consider the aggregate cytokine and health output to be a Markov 199 Random Field [24] . Just as the system evolves in a stochastic nature when left unattended, its responses to 200 perturbations will also be stochastic, however the possible future distribution of states is now based on the 201 components of the perturbation as well as the current system state. Successful interventions will then shift the 202 future state probability distribution towards health; more successful interventions will generate a larger move 203 towards health more often, though there can still exist a non-zero probability that the system state evolves 204 negatively rather than beneficially.
205
While GA is quite successful at healing at IIRABM under a wide range of conditions, it has a few drawbacks 206 which preclude it from being the ideal solution: 1) more extreme conditions (either very large injuries or 207 extremely virulent bacteria) require either a finer degree of control than is computationally tractable using GA, 208 as each sequential intervention multiplies the size of the search space by a factor of 912 (approximately 5 billion), 209 or more aggressive interventions; intervention multipliers were limited to a small set of values we considered 210 clinically tractable -removing this constraint would lead to an unconstrained search, increasing computational 211 cost and potentially generating implausible interventions; 2) adjusting the temporal density of interventions 212 requires a new run of the GA, which can be computationally expensive; 3) the GA does not have the ability to 213 react to non-responders and adjust the intervention accordingly -rather, it finds the single sequence of 214 interventions which (locally) maximizes the survival probability for a given patient population. We should note 215 that we do not claim to find the absolute optimum sequence of interventions for a given parameter set due to the 216 lack of general formal analytical convergence proofs for genetic algorithms [25, 26] and the fact that it is 217 computationally intractable to explore the entire intervention space, especially for multiple sequential 218 interventions. Additionally, many interventions can have opposing effects with the possibility of cancelling each 219 other out (i.e., GCSF augmentation leading to an increasing neutrophil population).
220
Future work will incorporate alternative machine learning algorithms, including deep reinforcement 221 learning [27] and Long Short Term Memory neural networks [28] for time-series prediction of aggregate cytokine 222 values. Both of these techniques would base putative interventions on the sequence of events that lead up to the 223 intervention. In this sense, the learning algorithm would adapt the putative intervention to an individual system 224 state rather than attempting to develop a single broad policy that would cover a certain class of injury.
225
These results strengthen the case for adaptive personalized medicine, a therapeutic strategy which adapts and 226 evolves in real time based on patient response. Rather than searching an astronomically large space for a 227 utilitarian intervention, personalized medicine techniques would respond to cytokine dynamics with an 228 individualized intervention for each patient at varying temporal scales. These things are theoretically possible 229 using GA, but at the present time, the computational expense limits the practicality of using this technique to 230 personalize treatments.
Materials and methods
232
The current investigation involves providing a proof-of-concept example of identifying whether effective controls 233 can be found for the IIRABM, and, by extension, for the treatment of sepsis. This initial proof-of-concept 234 constrains the problem by focusing a particular parameter configuration of the IIRABM with a mortality rate of 235 68%. We first employed a genetic algorithm (GA) to search for possible therapeutic interventions, and then 236 examined the generalizability of the optimal solutions across a wider range of stochastic replicates and additional 237 parameter sets with similar overall baseline mortality rates. The IIRABM was implemented in C++ and 238 simulations were performed on the Edison Cray XC30 Supercomputer at the National Energy Research Scientific 239 Computing Center and on the Beagle Cray XE6 Supercomputer at the University of Chicago. 240 We chose to train the GA on a single parameter set for 2 primary reasons: 1) A large number of parameter 241 sets can generate a realistic sepsis condition. Parameter sets that are relatively similar tend to have similar 242 mortality rates and similar simulated length-of-stays in the ICU. In this work, we explored the generalizability of 243 intervention solutions derived using the GA to help assess the future potential of utilizing GA as an in silico 244 drug-development technique . 2) The computational cost of running a genetic algorithm is substantial . A single 245 instance of this model simulating 90 days in the ICU will take approximately 4 minutes (depending on the speed 246 of the processor running the simulation). Each iteration of the GA gathers data from up to 2000 independent 247 simulation runs (where each run repeats the simulation 10 times using 10 stochastic replicates), and the GA can 248 run for 1000 or more generations before convergence when considering multi-stage interventions; each GA 249 experiment can utilize up to 1,000,000 cpu-hrs (equivalent to $100,000) [29] . 250 We have selected a parameter set (invasiveness=2, toxigenesis=5, host resilience=0.1, environmental 251 toxicity=2) which leads to simulated death approximately 80% of the time in the general case. This is illustrated 252 in Figure 6A ; here we show total health trajectories for 100 stochastic replicates of the above parameter set. The 253 systemic oxygen deficit (a proxy for total system damage) is plotted against the time for which the simulation 254 ran. Trajectories shown in red are simulations that die and trajectories shown in blue are simulations that heal 255 completely. From this set of outcome trajectories, we have chosen a specific trajectory/in silico patient with 256 which to train the GA. Given this specific patient's location in state space 24 hours post injury, we estimate that 257 they have a 68% chance of death. Note that this mortality rate is calculated in a different manner than the rate 258 referenced above. In the general case, this parameter set generates a mortality rate of 80%, meaning that when 259 the simulation's random number generator (RNG) is given 100 unique starting seeds, 80 of those simulations will 260 die (a population level outcome distribution). For the individual patient mortality rate, the simulation is paused 261 at the time step before the intervention would be applied (in this case, 24 hrs post injury); the simulation's RNG 262 is then reseeded a number of times to discover the mortality rate for a specific in silico patient at a specific 263 moment in time. Thus, the general case mortality rate represents the mortality rate for a specific parameter set, 264 while the individual patient mortality rate represents the mortality rate for a specific parameter set at a specific 265 instance in time. As discussed above, an individual patient does not have a fixed fate at any given point in time 266 (as long as their trajectory remains in the stochastic zone) and their probabilistic future outcome distribution is 267 time dependent and will evolve with the system. This is shown in Figure 6B ; this image displays 100 random 268 number generator (RNG) re-seedings, reseeded 24 hours post injury, of the specific trajectory we have chosen.
269
The utilization of stochastic replicates on a single patient allows the GA to sample the full range of responses 270 possible for a given intervention. 271 We have selected a set of cytokines and associated targets (PAF, TNFα, sTNFr, IL1, sIL1r, IL1ra, IFNγ, IL4, 272 IL8, IL10, IL12, and GCSF), which are the principal drivers of the inflammatory/immune dynamics expressed by 273 the model. In order to search for an optimal intervention strategy, we allow production of each of these targets to 274 be augmented or inhibited alone or as a group. For the purposes of this study, we consider an intervention to be 275 a set of signaling augmentations/inhibitions. An individual's chromosome is then a 1x12n vector, where n is the 276 number of independent sequential interventions, containing this information. The augmentation and inhibition 277 values are selected from the set: 0.05, 0.25, 0.5, 0.75, 1, 2, 5, 10, 20; inhibitory values are multiplicative (i.e., Augmentations are additive rather than multiplicative (i.e., S i,new = S i,old + (I i−1 ). This allows for a sustained 281 application of the intervention; were the augmentations to be multiplicative, then the simulation would quickly 282 produce results outside the realm of plausibility due to an exponential explosion in concentrations of cytokines 283
B A
Reseeding Point Fig 6. Panel A displays 100 stochastic trajectories generated by the IIRABM for a specific parameter set (Invasiveness=2; Host Resilience=0.1; Toxigenesis=5; Environmental Toxicity=2) with an injury with a radius of 33 cells. The total systemic oxygen deficit, an inverse measure of the in silico patient's health (y-axis) is presented as a function of time (x-axis). 82% of the simulated patients (red) end in death, while 18% heal completely (blue). The trajectories shown in panel B use the same parameter set as in panel A, however the run is started with a specific random number generator seed; the random number generator is re-seeded at 1 day post injury. At 1-day post injury, this specific patient has a 68% chance of death. whose values have been multiplied. To illustrate this, consider S 0 = 10; we wish to intervene on this cytokine's 284 production for 100 time steps by augmenting production by a value of 2 (20%) -if we use the additive method of 285 augmentation, on the 100th time step, 200 units of cytokine have been added. Alternatively, using a 286 multiplicative method, a 20% increase would be a multiplication by a factor of 1.2 -after 100 time steps, this 287 cytokine has increased by a factor of 1.2100, or approximately 80 million. 288 We define the fitness function as F = n i=1 (OD i + X i ), where OD represents the Oxygen Deficit, and is an 289 inverse measure of the patient's total health at the time when the fitness is evaluated and X is a measure of the 290 total infectious load in the system at the time when the fitness is evaluated, and n is the number of stochastic 291 replicates used. An optimal solution will minimize this fitness function (and thus maximize the patient's total 292 health). We train the GA on 10 stochastic replicates of an individual trajectory. These replicates are generated 293 by re-seeding the RNG at the time point when the intervention begins. This allows the GA to learn from a 294 possible range of responses and individual can have to a given intervention. The fitness is evaluated 12 hours 295 after the application of the final intervention (which has a maximum duration of 12 hours).
296
After the fitness is evaluated, we use the tournament selection method [30, 31] with a tournament size of 2 to 297 generate the breeding population. When breeding, each pair of progenitors produces two progeny using a uniform 298 crossover operator [32] . We continue this process until the algorithm has converged to a small set of possible 299 solutions, and select the solution that leads to the minimal fitness value as the intervention to be tested. We 300 evaluate the intervention according to three criteria: 1) outcome distribution in specific patient upon which the 301 GA was trained; 2) outcome distribution in a population of patients exposed to the same injury and microbial 302 infection; and 3) outcome distribution in a population of patients exposed to a range of injuries and microbial 303 infections.
304
Source code for the IIRABM with GA capability is available at https://bitbucket.org/cockrell/iirabm public. 305 Certain GA experiments used the EMEWS [33] framework with DEAP [34] to automate the GA process. 
